Skip to main content
. 2022 Apr 20;13:849364. doi: 10.3389/fphar.2022.849364

TABLE 4.

Anti-proliferative activities of compounds 3d and erlotinib against drug-resistant cancer cell lines.

IC50(μM)
KYSE70TR KYSE410TR KYSE450TR H1650TR HCC827GR
3d 7.17 ± 0.73 7.91 ± 0.61 10.02 ± 0.75 5.76 ± 0.33 2.38 ± 0.17
Erlotinib >20 >20 >20 >20 >20